WASHINGTON D.C.: On October 27, U.S. health officials said that even after the government shifts distribution to the commercial market next month, most people will still have access to Pfizer’s Paxlovid and Merck’s Lagevrio COVID-19 oral antiviral treatments for little or no cost. Commercial ordering for the treatments is set…Read More
Public will still have access to COVID19 antivirals after November 1
